Homepage Top Section1

The recommendation applies to children aged two to 11 years experiencing moderate-to-severe CSU who do not respond adequately to histamine-1 antihistamines and are naïve to anti-immunoglobulin E (IgE) therapy.

The approval was granted by the US Food and Drug Administration (FDA) and follows positive AMPLIFY Phase III trial results. This trial enrolled patients from 2019 to 2021.

The partnership will combine Evogene’s computational chemistry capabilities with the expertise of Dr Mark Adams’ team at QUT, focusing on therapy-resistant non-small cell lung cancer (NSCLC) and other

The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI. Under the agreement, both companies

Under the agreement, Biocodex will hold an exclusive worldwide licence to develop and commercialise Batten-1, which has been developed by THX Pharma for juvenile Batten disease (CLN3). Additionally,

The FDA accepted the gene therapy’s application under the accelerated approval pathway in May 2025. The CRL indicated that the FDA agreed in principle with the study protocol

The partnership represents the seventh agreement between the two companies and aims to expedite the delivery of new therapies to patients worldwide. Under the agreement, Innovent will utilise

The company’s fourth quarter revenues increased 1% to $12.5bn, and its growth portfolio surged 16% to $7.4bn. BMS reported non-GAAP earnings per share (EPS) of $6.15 for the

The collaboration will deploy radiology AI algorithms cleared by the US Food and Drug Administration (FDA) through Microsoft’s Precision Imaging Network, a component of its healthcare radiology solutions.